ClinConnect ClinConnect Logo
Search / Trial NCT06835218

PROCARE - PROstate Cancer Real World Evidence Registry

Launched by UROTRIALS COMPANY (GMBH) · Feb 13, 2025

Trial Information

Current as of July 09, 2025

Recruiting

Keywords

Prostate, Cancer, Metastatic, Systemic Therapy

ClinConnect Summary

The PROCARE study is a clinical trial aimed at understanding the treatment and progression of prostate cancer in patients with different stages of the disease. Specifically, it focuses on men who have experienced a rise in their PSA levels after previous treatments, such as surgery or radiation. This includes those with prostate cancer that has returned but hasn’t spread, those whose cancer has spread but is still responding to hormone therapy, and those whose cancer continues to progress despite hormone treatment. By gathering information from these various patient groups, researchers hope to better understand how to manage and treat prostate cancer over the long term.

To participate in this study, patients must be at least 18 years old and have been diagnosed with one of the specific types of prostate cancer mentioned. They should also be starting a new treatment for their cancer or have done so within the last four weeks. Participants will be monitored regularly to track their treatment and health outcomes. This study is currently recruiting, so if you or a loved one are eligible, you may have the opportunity to contribute to important research that could benefit future prostate cancer patients.

Gender

MALE

Eligibility criteria

  • Inclusion Criteria:
  • Adult prostate cancer patients (age ≥18 years).
  • Diagnosis at time of study inclusion Cohort 1: biochemical recurrence (BCR) after local curative intended treatment (e.g. radical prostatectomy, radiotherapy of the prostate or combination thereof) Cohort 2: non-metastatic castration-resistant prostate cancer (nmCRPC) or Cohort 3: metastatic hormone sensitive prostate cancer (mHSPC) or Cohort 4: metastatic castration-resistant prostate cancer (mCRPC) (irrespective of treatment choice, treatment line)
  • Patients who will receive a new line of systemic therapy at the time of study entry or up to 4 weeks thereafter. Regarding Cohort 4 this includes patients with a new diagnosis of mCRPC (=first line mCRPC) after either treatment for mHSPC or non-metastatic CRPC as well as patients with prior mCRPC treatments (2nd, 3rd, ... line).
  • For Cohorts 1, 2 and 3: Disease proven by clinical measures (i.e. standard imaging) to be either unsuitable for local salvage treatment (e.g. surgery, radiotherapy) or local treatment is declined by the patient.
  • Patients, who are able and willing to sign the informed consent form
  • Exclusion Criteria:
  • • Patients who are not eligible for observation due to severe comorbidities or unavailability according to the treating physician

About Urotrials Company (Gmbh)

UroTrials Company (GmbH) is a specialized clinical trial sponsor dedicated to advancing innovative therapies within the field of urology. With a strong focus on enhancing patient care, UroTrials collaborates with leading researchers and healthcare institutions to design and conduct rigorous clinical studies. The company is committed to adhering to the highest ethical standards and regulatory requirements, ensuring the integrity of its trials while fostering a patient-centric approach. Through its expertise in urological research, UroTrials aims to contribute significantly to the development of effective treatments and improve outcomes for patients with urological conditions.

Locations

Hamburg, , Germany

Ulm, , Germany

Tübingen, , Germany

Würzburg, Bavaria, Germany

Tübingen, Baden Württemberg, Germany

Jena, Thuringia, Germany

Ulm, Baden Württemberg, Germany

Magdeburg, Saxony Anhalt, Germany

Bonn, North Rhine Westphalia, Germany

Augsburg, Bavaria, Germany

Leipzig, Saxony, Germany

Bayreuth, Bavaria, Germany

Nürnberg, Bavaria, Germany

Gießen, Hesse, Germany

Marburg, Hesse, Germany

Wetzlar, Hesse, Germany

Braunschweig, Lower Saxony, Germany

Herzberg, Lower Saxony, Germany

Wilhelmshaven, Lower Saxony, Germany

Bayenthal, North Rhine Westphalia, Germany

Bergisch Gladbach, North Rhine Westphalia, Germany

Duisburg, North Rhine Westphalia, Germany

Essen, North Rhine Westphalia, Germany

Herne, North Rhine Westphalia, Germany

Paderborn, North Rhine Westphalia, Germany

Wuppertal, North Rhine Westphalia, Germany

Würselen, North Rhine Westphalia, Germany

Trier, Rhineland Palatinate, Germany

Neunkirchen, Saarland, Germany

Lübeck, Schleswig Holstein, Germany

Berlin, Brandenburg, Germany

Karlsruhe, Rhineland Palatinate, Germany

Heidelberg, Baden Württemberg, Germany

Nürtingen, Baden Württemberg, Germany

Hildesheim, Lower Saxony, Germany

Magdeburg, Lower Saxony, Germany

Rostock, Mecklenburg Western Pomerania, Germany

Bonn, North Rhine Westphalia, Germany

Halle, Saxony Anhalt, Germany

Heidelberg, , Germany

Nürtingen, , Germany

Patients applied

0 patients applied

Trial Officials

Marc-Oliver Grimm, Professor

Study Director

University Hospital Jena

Boris Hadaschik, Professor

Study Director

University Hospital, Essen

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported